|
1
|
Raza A and Sood GK: Hepatocellular
carcinoma review: Current treatment, and evidence-based medicine.
World J Gastroenterol. 20:4115–4127. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
3
|
Perz JF, Armstrong GL, Farrington LA,
Hutin YJ and Bell BP: The contributions of hepatitis B virus and
hepatitis C virus infections to cirrhosis and primary liver cancer
worldwide. J Hepatol. 45:529–538. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hu HG, Scholten I, Gruss C and Knippers R:
The distribution of the DEK protein in mammalian chromatin. Biochem
Biophys Res Commun. 358:1008–1014. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Waldmann T, Baack M, Richter N and Gruss
C: Structure-specific binding of the proto-oncogene protein DEK to
DNA. Nucleic Acids Res. 31:7003–7010. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Waldmann T, Eckerich C, Baack M and Gruss
C: The ubiquitous chromatin protein DEK alters the structure of DNA
by introducing positive supercoils. J Biol Chem. 277:24988–24994.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Waldmann T, Scholten I, Kappes F, Hu HG
and Knippers R: The DEK protein: an abundant and ubiquitous
constituent of mammalian chromatin. Gene. 343:1–9. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
von Lindern M, Fornerod M, van Baal S,
Jaegle M, de Wit T, Buijs A and Grosveld G: The translocation
(6;9), associated with a specific subtype of acute myeloid
leukemia, results in the fusion of two genes, dek and can, and the
expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell
Biol. 12:1687–1697. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Soekarman D, von Lindern M, Daenen S, de
Jong B, Fonatsch C, Heinze B, Bartram C, Hagemeijer A and Grosveld
G: The translocation (6;9) (p23;q34) shows consistent rearrangement
of two genes and defines a myeloproliferative disorder with
specific clinical features. Blood. 79:2990–2997. 1992.PubMed/NCBI
|
|
10
|
Kappes F, Waldmann T, Mathew V, Yu J,
Zhang L, Khodadoust MS, Chinnaiyan AM, Luger K, Erhardt S,
Schneider R, et al: The DEK oncoprotein is a Su(var) that is
essential to heterochromatin integrity. Genes Dev. 25:673–678.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fu GK, Grosveld G and Markovitz DM: DEK,
an autoantigen involved in a chromosomal translocation in acute
myelogenous leukemia, binds to the HIV-2 enhancer. Proc Natl Acad
Sci USA. 94:1811–1815. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McGarvey T, Rosonina E, McCracken S, Li Q,
Arnaout R, Mientjes E, Nickerson JA, Awrey D, Greenblatt J,
Grosveld G, et al: The acute myeloid leukemia-associated protein,
DEK, forms a splicing-dependent interaction with exon-product
complexes. J Cell Biol. 150:309–320. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Alexiadis V, Waldmann T, Andersen J, Mann
M, Knippers R and Gruss C: The protein encoded by the
proto-oncogene DEK changes the topology of chromatin and reduces
the efficiency of DNA replication in a chromatin-specific manner.
Genes Dev. 14:1308–1312. 2000.PubMed/NCBI
|
|
14
|
Kavanaugh GM, Wise-Draper TM, Morreale RJ,
Morrison MA, Gole B, Schwemberger S, Tichy ED, Lu L, Babcock GF,
Wells JM, et al: The human DEK oncogene regulates DNA damage
response signaling and repair. Nucleic Acids Res. 39:7465–7476.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim DW, Chae JI, Kim JY, Pak JH, Koo DB,
Bahk YY and Seo SB: Proteomic analysis of apoptosis related
proteins regulated by proto-oncogene protein DEK. J Cell Biochem.
106:1048–1059. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee KS, Kim DW, Kim JY, Choo JK, Yu K and
Seo SB: Caspase-dependent apoptosis induction by targeted
expression of DEK in Drosophila involves histone acetylation
inhibition. J Cell Biochem. 103:1283–1293. 2008. View Article : Google Scholar
|
|
17
|
Casas S, Nagy B, Elonen E, Aventín A,
Larramendy ML, Sierra J, Ruutu T and Knuutila S: Aberrant
expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia.
Leuk Lymphoma. 44:1935–1941. 2003. View Article : Google Scholar
|
|
18
|
Lin L, Piao J, Gao W, Piao Y, Jin G, Ma Y,
Li J and Lin Z: DEK over expression as an independent biomarker for
poor prognosis in colorectal cancer. BMC Cancer. 13:3662013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Piao J, Shang Y, Liu S, Piao Y, Cui X, Li
Y and Lin Z: High expression of DEK predicts poor prognosis of
gastric adenocarcinoma. Diagn Pathol. 9:672014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ahmad I and Rao DN: Chemistry and biology
of DNA methyltransferases. Crit Rev Biochem Mol Biol. 31:361–380.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gardiner-Garden M and Frommer M: CpG
islands in vertebrate genomes. J Mol Biol. 196:261–282. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cottrell SE: Molecular diagnostic
applications of DNA methylation technology. Clin Biochem.
37:595–604. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stresemann C, Brueckner B, Musch T,
Stopper H and Lyko F: Functional diversity of DNA methyltransferase
inhibitors in human cancer cell lines. Cancer Res. 66:2794–2800.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sitwala KV, Adams K and Markovitz DM: YY1
and NF-Y binding sites regulate the transcriptional activity of the
dek and dek-can promoter. Oncogene. 21:8862–8870. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Carro MS, Spiga FM, Quarto M, Di Ninni V,
Volorio S, Alcalay M and Müller H: DEK Expression is controlled by
E2F and deregulated in diverse tumor types. Cell Cycle.
5:1202–1207. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lü ZL, Luo DZ and Wen JM: Expression and
significance of tumor-related genes in HCC. World J Gastroenterol.
11:3850–3854. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin LJ and Chen LT: The role of DEK
protein in hepatocellular carcinoma for progression and prognosis.
Pak J Med Sci. 29:778–782. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yi HC, Liu YL, You P, Pan JS, Zhou JY, Liu
ZJ and Zhang ZY: Overexpression of DEK gene is correlated with poor
prognosis in hepatocellular carcinoma. Mol Med Rep. 11:1318–1323.
2015.
|
|
29
|
Kondoh N, Wakatsuki T, Ryo A, Hada A,
Aihara T, Horiuchi S, Goseki N, Matsubara O, Takenaka K, Shichita
M, et al: Identification and characterization of genes associated
with human hepatocellular carcinogenesis. Cancer Res. 59:4990–4996.
1999.PubMed/NCBI
|
|
30
|
Roman-Gomez J, Jimenez-Velasco A, Agirre
X, Cervantes F, Sanchez J, Garate L, Barrios M, Castillejo JA,
Navarro G, Colomer D, et al: Promoter hypomethylation of the LINE-1
retrotransposable elements activates sense/antisense transcription
and marks the progression of chronic myeloid leukemia. Oncogene.
24:7213–7223. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li S, Hansman R, Newbold R, Davis B,
McLachlan JA and Barrett JC: Neonatal diethylstilbestrol exposure
induces persistent elevation of c-fos expression and
hypomethylation in its exon-4 in mouse uterus. Mol Carcinog.
38:78–84. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dang CV, O'donnell KA and Juopperi T: The
great MYC escape in tumorigenesis. Cancer Cell. 8:177–178. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rodriguez BAT, Weng YI, Liu TM, Zuo T, Hsu
PY, Lin CH, Cheng AL, Cui H, Yan PS and Huang TH: Estrogen-mediated
epigenetic repression of the imprinted gene cyclin-dependent kinase
inhibitor 1C in breast cancer cells. Carcinogenesis. 32:812–821.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sato N, Maitra A, Fukushima N, van Heek
NT, Matsubayashi H, Iacobuzio-Donahue CA, Rosty C and Goggins M:
Frequent hypomethylation of multiple genes overexpressed in
pancreatic ductal adenocarcinoma. Cancer Res. 63:4158–4166.
2003.PubMed/NCBI
|
